Digest Network Come funziona
Network
/
Società
Co
Non verificato

Corcept Therapeutics Incorporated

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

51 comunicati stampa

Guarda tutti i comunicati
27/10/2026
Salute
Comunicazione
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Telefonia e Varie
Finanza
Mercato azionario
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
26/10/2026
Biotecnologia
Farmaceutica
Oncologia
Salute
Vetrine/Shopping
Medicina - Varie
Industria
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
20/10/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Industria
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
23/09/2026
Mercato del lavoro
Oncologia
Salute
Farmaceutica
Cardiologia
Biotecnologia
Corcept Announces Planned Leadership Transition
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
18/09/2026
Oncologia
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
29/07/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
22/07/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Farmaceutica
Salute
Oncologia
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
17/06/2026
Industria
Biotecnologia
Igiene alimentare
Salute
Sanità
Farmaceutica
Oncologia
Scienza
Medicina - Varie
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
06/06/2026
Scienza
Salute
Medicina - Varie
Biotecnologia
Farmaceutica
Sanità
Oncologia
Eventi
Fiere
Industria
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
29/05/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0